News | April 01, 2022
Sumitomo Chemical to build new API and intermediates plant in Japan
The plant is scheduled to come on stream in September 2024
The plant is scheduled to come on stream in September 2024
The event will have a mix of policymakers, national and international leaders from the pharma industry, MSME, innovators, academic and research fraternity
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Dupixent peak sales ambition raised to more than €13 billion
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
